Quoin Pharmaceuticals Statistics
Total Valuation
QNRX has a market cap or net worth of $10.20 million. The enterprise value is -$5.31 million.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, before market open.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
QNRX has 1.68 million shares outstanding. The number of shares has increased by 416.87% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.68M |
| Shares Change (YoY) | +416.87% |
| Shares Change (QoQ) | -87.88% |
| Owned by Insiders (%) | 3.40% |
| Owned by Institutions (%) | 34.69% |
| Float | 1.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.61 |
| Quick Ratio | 3.38 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -141.59% and return on invested capital (ROIC) is -73.86%.
| Return on Equity (ROE) | -141.59% |
| Return on Assets (ROA) | -56.41% |
| Return on Invested Capital (ROIC) | -73.86% |
| Return on Capital Employed (ROCE) | -109.75% |
| Weighted Average Cost of Capital (WACC) | 11.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.16M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.42% in the last 52 weeks. The beta is 1.82, so QNRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.82 |
| 52-Week Price Change | -22.42% |
| 50-Day Moving Average | 8.24 |
| 200-Day Moving Average | 10.09 |
| Relative Strength Index (RSI) | 34.54 |
| Average Volume (20 Days) | 240,836 |
Short Selling Information
The latest short interest is 7,634, so 0.45% of the outstanding shares have been sold short.
| Short Interest | 7,634 |
| Short Previous Month | 14,672 |
| Short % of Shares Out | 0.45% |
| Short % of Float | 0.58% |
| Short Ratio (days to cover) | 0.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.29M |
| Pretax Income | -15.80M |
| Net Income | -15.80M |
| EBITDA | -16.19M |
| EBIT | -16.29M |
| Earnings Per Share (EPS) | -$14.80 |
Full Income StatementBalance Sheet
The company has $18.75 million in cash and $2.32 million in debt, with a net cash position of $16.42 million or $9.75 per share.
| Cash & Cash Equivalents | 18.75M |
| Total Debt | 2.32M |
| Net Cash | 16.42M |
| Net Cash Per Share | $9.75 |
| Equity (Book Value) | 13.12M |
| Book Value Per Share | 8.76 |
| Working Capital | 14.46M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 100,000 |
| Net Borrowing | -600,000 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
